You provide basic demographic information, health history, current medications, and your weight management goals
For these reasons, people are taking to microdosing weight-loss drugs, or using less than the dose recommended by the manufacturer
Amycretin SC (24.3% at 36 wk) achieved this remarkable result in a small Phase 1b/2a trial with only 36 weeks of treatment
The degree of gastric emptying delay is dose-dependent and most pronounced during treatment initiation and dose escalation
Novo will, however, keep patent protection for semaglutide in Europe and Japan until 2033, and in the US until 2032
It is important to note that Semaglutide is not the only injectable medication available for weight loss